(firstQuint)Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial).

 The Endurance 2 Trial is a phase IV open label clinical study to assess the need for ongoing intravitreal aflibercept injections after the 3-year VISTA DME (VGFT-OD-1009) end-point.

 Subjects will be treated with intravitreal aflibercept injections pro re nata (PRN) based on the presence of CR-DME (Clinically Relevant-DME).

 In addition, subjects who meet re-treatment criteria will be eligible for focal laser treatment every 90 days.

 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial)@highlight

The Endurance 2 Trial is to determine the need for ongoing intravitreal aflibercept injections for patients with diabetic macular edema who have previously completed the VISTA study.

